KCNJ11

ATP-sensitive inward rectifier potassium channel 11 · Q14654 · KCNJ11 on Sugi Atlas →

22,406 patent compounds predicted against KCNJ11, 11,186 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1289338	0.57	17/20
SCHEMBL589730	0.56	17/20
SCHEMBL1002731	0.73	15/20
SCHEMBL561467	0.62	13/20
SCHEMBL562109	0.62	13/20
Naminidil (SCHEMBL1650535)	1.00	9/20
Pinacidil Anhydrous (SCHEMBL65786)	0.53	9/20
Pinacidil Anhydrous (SCHEMBL504208)	0.53	9/20
SCHEMBL809999	0.48	9/20
SCHEMBL810062	0.48	9/20
SCHEMBL810190	0.48	9/20
SCHEMBL810341	0.48	9/20
SCHEMBL811109	0.48	9/20
Pinacidil Anhydrous (SCHEMBL65787)	1.00	8/20
Pinacidil Anhydrous (SCHEMBL1650693)	1.00	8/20
SCHEMBL777068	0.61	7/20
Naminidil (SCHEMBL1159568)	0.56	7/20
SCHEMBL880238	0.41	6/20
SCHEMBL1164037	0.55	5/20
SCHEMBL256602	0.48	5/20

Clinical trials — most relevant to KCNJ11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes	PHASE4	COMPLETED
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes	PHASE4	UNKNOWN
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Sandostatine® LP and Hyperinsulinism	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus	PHASE2	COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Interaction of Potassium and Genetic Risk Variants on Diabetes Risk	nan	COMPLETED
Feasibility of Improving Risk Stratification in Brugada Syndrome	nan	COMPLETED
Gene Study for Infantile Onset Diabetes	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Genetic Study for Infantile Onset Diabetes Mellitus	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNJ11 binder may also engage these)

Protein	Name	Similarity
O02822	—	1.000	O02822 →
Q61743	—	1.000	Q61743 →
Q9JHJ9	—	1.000	Q9JHJ9 →
P70673	—	0.999	P70673 →
Q9NPI9	—	0.996	Q9NPI9 →
P86046	—	0.993	P86046 →
P97794	—	0.990	P97794 →
Q9Z307	—	0.990	Q9Z307 →
Q4TZY1	—	0.989	Q4TZY1 →
O70617	—	0.989	O70617 →
Q63664	—	0.989	Q63664 →
O19182	—	0.989	O19182 →
Q9QZ65	—	0.988	Q9QZ65 →
P52190	—	0.988	P52190 →
P35561	—	0.988	P35561 →
P52191	—	0.988	P52191 →
O60928	—	0.988	O60928 →
P52185	—	0.988	P52185 →
P63253	—	0.987	P63253 →
B7U540	—	0.987	B7U540 →
KCNJ2	Inward rectifier potassium channel 2	0.987	landscape →
KCNJ8	ATP-sensitive inward rectifier potassium channel 8	0.987	landscape →
P52186	—	0.987	P52186 →
Q9MYY9	—	0.987	Q9MYY9 →
P52189	—	0.986	P52189 →
P49656	—	0.986	P49656 →
Q64273	—	0.986	Q64273 →
P52187	—	0.986	P52187 →
P52188	—	0.986	P52188 →
Q64198	—	0.986	Q64198 →